The new tool was introduced in conjunction with DIA 2016 this week, June 26-30, in Philadelphia, Pennslyvania.
“Building an IRT-like system for every early phase study, investigator initiated study, or extension study ends up costing a sponsor more time, effort, and money,” Ryan Keane, executive director of business development at endpoint, told Outsourcing-Pharma.com. For this reason, many sponsors choose not to use IRT, especially in early phase studies.
“While this decision may be the right one economically at the time, the sponsor is still left with the clinical task of manually managing these studies via an antiquated, paper-based methodology, as well as having their clinical supplies management team manage their inventory across hundreds of both non-IRT and IRT studies,” explained Keane.
According to Keane, this requires “thousands of hours per year to manage,” while levering none of the automated IRT supplies features, which can expose sponsors to regulatory challenges around drug accountability.
With DRIVE, Keane explained that users can manage all elements of non-IRT and endpoint IRT studies electronically within a single system, with the ability to see supply at depots through a single view. “All of this can be accomplished without the excessive costs of separate electronic products or tools, forecasting data integrations to other vendors and manual paper-based efforts,” he added.